Clinical trials: Hepatobiliary Disorders
Alcohol-associated Fatty Liver Disease
High-Plant-Protein-Diet or High-Animal-Protein-Diet for Improving Alcoholic Fatty Liver Disease
Alcohol-associated liver disease (ALD) is a major cause of mortality from advanced liver disease, accounting for 47.9% of cirrhosis-related deaths and 30% of hepatocellular carcinoma-related deaths annually.
- Trial name
- NCT07897981
- Testing
- whey protein powder, soy protein powder
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Li Lab,MD
Nonalcoholic Steatohepatitis, Metabolic Syndrome
The Role of Leptin Receptors in NASH
NAFLD is a spectrum of liver diseases associated with varying degrees of hepatic steatosis, inflammation, and in some cases, fibrosis.
- Trial name
- NASH (NCT00583999)
- Testing
- no interventions, only regular blood-draw
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
NAFLD
NAFLD in Patient of Hypothyroidism
Nonalcoholic fatty liver disease (NAFLD) is the most important chronic liver disease in the western world, affecting almost 30% of the general population.
- Trial name
- NCT05813301
- Volunteers
- 100 people
- Sponsor
- Assiut University
Non-Alcoholic Fatty Liver Disease
A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.
Aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of XTYW007 in healthy subjects and healthy subjects with elevated LDL-C, as well as studying the effects of food on…
- Trial name
- NCT07407634
- Where
- China
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Morbid Obesity, Non-alcoholic Fatty Liver Disease
Intestinal Microbiota and NAFLD Pre and Post Bariatric Surgery
Non-alcoholic fatty liver disease (NAFLD) includes benign hepatic simple steatosis (SS) and steatohepatitis (NASH), which is characterised by inflammation leading to fibrosis and cirrhosis.
- Trial name
- NCT01856465
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Johane Allard
Chronic Liver Disease
Study to Evaluate Efficacy, Safety and Tolerability of PENNEL Capsule in the Patients With Chronic Liver Disease
The test agent in this study is a product of biphenylmethyl dicarboxylate (BDD) with garlic oil. The two components were confirmed to have complementary effects because of different operational mechanism in animal experiments…
- Trial name
- NCT01393665
- Testing
- PENNEL capsule
- Where
- 2 sites in South Korea
- Volunteers
- 88 people
- Sponsor
- PharmaKing
Hepatitis, Liver Cirrhosis
Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease
BACKGROUND The insulin-like growth factor system (IGFs) plays an important role in cell growth and differentiation. Nevertheless, the roles played by insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding…
- Conditions
- Hepatitis, Liver Cirrhosis, Hepatocellular Carcinoma
- Trial name
- NCT00679692
- Where
- Taiwan
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Cystic Fibrosis Liver Disease
Longitudinal Assessment of Transient Elastography in Cystic Fibrosis
To determine if transient elastography (TE), when combined with ultrasound (US) pattern characterization can improve the prediction of progression to a nodular pattern on US.
- Trial name
- NCT03001388
- Testing
- Transient Elastography (TE)
- Where
- 8 sites in United States, Canada
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Alcohol Use Disorder, Alcohol-related Liver Disease
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
This protocol describes a randomized controlled trial testing the effectiveness and implementability of the CHESS Health Connections smartphone application among patients with alcohol-associated liver disease (ALD) at two medical…
- Trial name
- IMPACT-ALD (NCT06305624)
- Testing
- Connections App
- Where
- 3 sites in United States
- Volunteers
- 298 people
- Sponsor
- University of Wisconsin, Madison
Cancer, Cancer of Pancreas
Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer
PURPOSE: To determine the prognostic properties of a comprehensive evaluation of body composition and physical function in patients with GI-HEP cancer from point of diagnosis and throughout the treatment trajectory.
- Conditions
- Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Esophagus
- Trial name
- NCT03347162
- Where
- Denmark
- Volunteers
- 1,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
Phase II trial to study the effectiveness of BMS-247550 in treating patients who have liver or gallbladder cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct
- Trial name
- NCT00023946
- Testing
- ixabepilone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Metabolic Disorders, Non-alcoholic Steatohepatitis
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in…
- Trial name
- NCT04142424
- Testing
- AZD2693
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
NAFLD
Ketohexokinase Inhibition in NAFLD
Fructose is a big contributor to the development of non-alcoholic fatty liver disease (NAFLD). Inhibiting ketohexokinase (KHK), the enzyme catalyzing the first committed step in fructose metabolism, is thought to reduced…
- Trial name
- KHKi (NCT05463575)
- Testing
- Ketohexokinase inhibition
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Liver Diseases, Blood Disorder
NASH Fitness Intervention in Thrombosis Trial (NASHFit)
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States. The most advanced forms of NAFLD are associated with increased liver-related mortality and lower overall survival.
- Conditions
- Liver Diseases, Blood Disorder, Digestive System Disease
- Trial name
- NCT03518294
- Testing
- Aerobic Exercise
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Milton S. Hershey Medical Center
Liver Diseases
Randomised Controlled Study of Popofol Versus Midazolam as Sedation in Endoscopy With Advanced Liver Disease.
Gastrointestinal endoscopy is a frequent procedure in the patients with advanced liver disease. It requires variable degree of sedation ranging from minimal sedation to general anesthesia aiming for relieving pain, anxiety, and…
- Trial name
- NCT03063866
- Testing
- Propofol, Midazolam, Fentanyl
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sherief Abd-Elsalam
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic…
- Trial name
- LYNX (NCT07270601)
- Testing
- Verasonics NXT Data Acquisition System, Philips EPIQ Elite, EchoSense FibroScan
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- ContextVision AB
NASH - Nonalcoholic Steatohepatitis
A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F4 NASH.
- Trial name
- NCT03976401
- Testing
- EFX
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 110 people
- Sponsor
- Akero Therapeutics, Inc
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes
Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)
The aim of this study is to evaluate the effect of dapagliflozin on liver function of patient with NAFLD and T2DM.
- Trial name
- NCT05459701
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Rehab Werida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.